Cardiol Therapeutics Class Stock Performance
| CRDL Stock | USD 1.36 0.07 4.90% |
The firm shows a Beta (market volatility) of 0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cardiol Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cardiol Therapeutics is expected to be smaller as well. At this point, Cardiol Therapeutics has a negative expected return of -0.76%. Please make sure to confirm Cardiol Therapeutics' potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Cardiol Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cardiol Therapeutics Class has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
1 | Cardiol Therapeutics Trading Up 1.1 percent - MarketBeat | 09/26/2024 |
2 | Why Cardiol Therapeutics Stock Is Down 20 percent Today | 10/09/2024 |
3 | Are Medical Stocks Lagging Cardiol Therapeutics This Year | 10/22/2024 |
4 | Cardiol Therapeutics Reports Promising Phase II Results - TipRanks | 11/18/2024 |
5 | What is HC Wainwrights Forecast for CRDL FY2024 Earnings - MarketBeat | 11/22/2024 |
| Begin Period Cash Flow | 59.5 K |
Cardiol |
Cardiol Therapeutics Relative Risk vs. Return Landscape
If you would invest 227.00 in Cardiol Therapeutics Class on September 14, 2024 and sell it today you would lose (91.00) from holding Cardiol Therapeutics Class or give up 40.09% of portfolio value over 90 days. Cardiol Therapeutics Class is currently does not generate positive expected returns and assumes 3.0787% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Cardiol, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cardiol Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiol Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cardiol Therapeutics Class, and traders can use it to determine the average amount a Cardiol Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2478
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRDL |
Estimated Market Risk
| 3.08 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.76 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cardiol Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cardiol Therapeutics by adding Cardiol Therapeutics to a well-diversified portfolio.
Cardiol Therapeutics Fundamentals Growth
Cardiol Stock prices reflect investors' perceptions of the future prospects and financial health of Cardiol Therapeutics, and Cardiol Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardiol Stock performance.
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 105.77 M | ||||
| Shares Outstanding | 81.6 M | ||||
| Price To Book | 15.86 X | ||||
| Price To Sales | 1,069 X | ||||
| Gross Profit | 78.76 K | ||||
| EBITDA | (29.59 M) | ||||
| Net Income | (28.13 K) | ||||
| Cash And Equivalents | 70.45 M | ||||
| Cash Per Share | 1.14 X | ||||
| Total Debt | 174.34 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (25.18 K) | ||||
| Earnings Per Share | (0.38) X | ||||
| Market Capitalization | 116.86 M | ||||
| Total Asset | 36.7 M | ||||
| Retained Earnings | (142.58 M) | ||||
| Working Capital | 51.63 M | ||||
About Cardiol Therapeutics Performance
By examining Cardiol Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Cardiol Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cardiol Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 32.86 | 31.21 | |
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (0.77) | (0.80) | |
| Return On Equity | (1.00) | (1.05) |
Things to note about Cardiol Therapeutics performance evaluation
Checking the ongoing alerts about Cardiol Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cardiol Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardiol Therapeutics generated a negative expected return over the last 90 days | |
| Cardiol Therapeutics may become a speculative penny stock | |
| Cardiol Therapeutics has high historical volatility and very poor performance | |
| Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (28.13 K) with profit before overhead, payroll, taxes, and interest of 78.76 K. | |
| Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14. | |
| Cardiol Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: What is HC Wainwrights Forecast for CRDL FY2024 Earnings - MarketBeat |
- Analyzing Cardiol Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardiol Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cardiol Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardiol Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardiol Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardiol Therapeutics' stock. These opinions can provide insight into Cardiol Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.